
CFRXQ
Healthcare · Biotechnology · $107 market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2023
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 14, 2023 | After the close | -0.66 | -0.50 | +24.2% |
| Aug 14, 2023 | Before the open | -1.81 | -1.94 | -7.2% |
| May 15, 2023 | Before the open | -10.83 | -0.69 | +93.6% |
| Mar 16, 2023 | Time not confirmed | -27.20 | -16.12 | +40.7% |
| Nov 14, 2022 | Before the open | -18.40 | -34.40 | -87.0% |
| Aug 15, 2022 | Before the open | -26.40 | -36.80 | -39.4% |
| May 16, 2022 | Before the open | -23.80 | -40.80 | -71.4% |
| Mar 24, 2022 | Time not confirmed | -0.26 | -0.11 | +58.0% |
| Nov 15, 2021 | Before the open | -22.40 | -10.40 | +53.6% |
| Aug 13, 2021 | Before the open | -22.40 | -11.20 | +50.0% |
| May 14, 2021 | Before the open | -23.60 | -14.40 | +39.0% |
| Mar 30, 2021 | Time not confirmed | -0.32 | -0.23 | +27.0% |
| Nov 13, 2020 | Before the open | -32.00 |
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational…
| -20.84 |
| +34.9% |
| Aug 14, 2020 | Before the open | -17.60 | -41.26 | -134.4% |
| May 15, 2020 | Before the open | -67.20 | -41.71 | +37.9% |
| Mar 18, 2020 | Time not confirmed | -0.79 | -1.11 | -40.5% |
| Nov 12, 2019 | Before the open | -40.00 | -56.00 | -40.0% |
| Aug 9, 2019 | Before the open | -72.00 | -88.00 | -22.2% |
| May 10, 2019 | Before the open | -88.00 | -62.56 | +28.9% |
| Mar 14, 2019 | Time not confirmed | -0.10 | 0.70 | +800.0% |
| Nov 8, 2018 | Before the open | -76.00 | -78.72 | -3.6% |
| Aug 9, 2018 | Before the open | -76.00 | -80.00 | -5.3% |
| May 10, 2018 | Before the open | -72.00 | -74.20 | -3.1% |
| Mar 15, 2018 | Time not confirmed | -0.10 | -0.60 | -500.0% |